Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7624612 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL854090 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL1773132 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL7612611 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL7563162 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL11806608 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL2404356 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL2162933 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL79441 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL17027772 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113121304-A | Synthetic method of p-bromooctylbenzene and derivatives thereof | 河北松辰医药科技有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-106398080-B | A kind of ammonium cross-linking type block copolymer/graphene composite material and preparation method thereof | 北京化工大学 | 2018-12-04 | — | — | CN | claimed |
| CN-106398080-A | Aminated cross-linked segmented copolymer/graphene composite material and preparation method thereof | 北京化工大学 | 2017-02-15 | — | — | CN | claimed |
| CN-117715912-B | Macrocyclic ligands with picolinate groups, complexes thereof and medical uses | 法国加柏公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4377316-B1 | MACROCYCLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES THEREOF AND MEDICAL USES THEREOF | GUERBET SA (FR) | 2025-12-03 | — | — | EP | disclosed |
| US-20240352011-A1 | Macrocyclic Ligands with Picolinate Group(s), Complexes and Medical Uses Thereof | GUERBET (FR) | 2024-10-24 | — | — | US | disclosed |
| WO-2024140595-A1 | TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118255685-A | Tricyclic compound, pharmaceutical composition and application thereof | 珂阑(上海)医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-4377316-A1 | MACROCYCLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES AND MEDICAL USES THEREOF | Guerbet (FR) | 2024-06-05 | — | — | EP | disclosed |
| CN-117715912-A | Macrocyclic ligands with picolinate groups, complexes thereof and medical uses | 法国加柏公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4124361-B1 | MACROCYCLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES THEREOF AND MEDICAL USES THEREOF | GUERBET SA (FR) | 2024-01-31 | — | — | EP | disclosed |
| EP-0327306-A2 | Leukotriene B4 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-08-09 | — | — | EP | disclosed |
| EP-0313697-A1 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-05-03 | — | — | EP | disclosed |
| US-4820719-A | ANTIALLERGENS, ANTIINFLAMMATORY, ANTIISCHEMIC AND HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0296731-A1 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1988-12-28 | — | — | EP | disclosed |
| EP-0296732-A1 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1988-12-28 | — | — | EP | disclosed |
| US-4730005-A | DITHIA-ALKANEDIOIC ACIDS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-03-08 | — | — | US | disclosed |
| EP-0168902-B1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1987-09-30 | — | — | EP | disclosed |
| EP-0202759-A2 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1986-11-26 | — | — | EP | disclosed |
| EP-0168902-A1 | Leukotriene antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1986-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352011-A1 | Macrocyclic Ligands with Picolinate Group(s), Complexes and Medical Uses Thereof | MPI, GRPR, SSTR3 | TDP1 4382/4885SIGMAR1 1663/4885MAOA 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.